Amarantus CEO Gerald Commissiong Elected to Biotechnology Industry Organization Committees
SAN FRANCISCO and GENEVA, Oct. 20, 2014 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostics and therapeutics for Alzheimer's disease, Parkinson's disease and ophthalmological disorders, announced that President & CEO, Gerald Commissiong, was elected to three Biotechnology Industry Organization("BIO") committees: the Healthcare Reform & Reimbursement Committee, the Personalized Medicine and Diagnostics Working Group, and the 17th Annual BIO CEO & Investor Conference Advisory Committee.
"BIO is a critical organization that represents the biopharmaceutical industry to work with policy-makers who set guidelines for biotechnology product development and commercial oversight in the United States," said Gerald E. Commissiong, President & CEO of Amarantus. "I'm very happy to become formally involved in this important effort. BIO is the world's largest trade organization representing biotech organizations across the United States and in more than 30 other nations. Its initiatives include improving products, from development to commercialization, which are invaluable to patients in the safest and most efficacious manner possible."
BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling "innovations transforming our world" and the BIO Newsletter is the organization's bi-weekly email newsletter." Subscribe to the BIO Newsletter.
About Amarantus BioScience Holdings, Inc.
Amarantus BioScience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis. AMBS has licensed Eltoprazine ("Eltoprazine"), a phase 2b ready small molecule indicated for Parkinson's Levodopa induced dyskinesia and Adult ADHD. AMBS has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test(R)") for Alzheimer's disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. AMBS also owns intellectual property for the diagnosis of Parkinson's disease ("NuroPro") and the discovery of neurotrophic factors ("PhenoGuard"). Amarantus operations are located at Janssen Labs @QB3 in San Francisco, CA. For further information please visit www.Amarantus.com, or connect with the Company on Facebook, LinkedIn, Twitter and Google+.
CONTACT: Amarantus Bioscience Holdings, Inc. Aimee Boutcher, Investor Relations 408.737.2734 x 101 firstname.lastname@example.org Planet Communications Deanne Eagle, Media Contact (917) 837-5866